In this photo illustration, the injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois. Novo Nordisk (NVO), the maker of the ...

Novo Nordisk has been on the hunt for differentiated ... It’s found a contender with preclinical data indicating it can lead to greater weight loss as part of a drug combination and also prevent ...

Even though the stock is down notably from the peak price it hit last year, it's still doing far better than in the pre-approval days. Competitors are biting at its heels in the weight loss segment, ...

Register for free now. Novo Nordisk A/S NVO has been on a tear in the weight loss drug race, but its stock is slimming down for all the wrong reasons. Shares have plunged 44.14% over the past year ...

Investing.com -- Novo Nordisk A/S (NYSE ... The trial results showed significant A1C reduction and weight loss, which are seen as competitive to Novo’s offerings. The ACHIEVE-1 trial results ...

Novo Nordisk to Pay $2 Billion for New Weight Loss Drug TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion ...

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer ...

It is also approved for similar trials in the U.S. The deal comes as Novo Nordisk works to expand its lineup of advanced weight-loss treatments. Although the company’s drugs have been popular ...